



**HAL**  
open science

## Severe diffuse alveolar hemorrhage related to autoimmune disease: a multicenter study

Adrien Mirouse, Antoine Parrot, Vincent Audigier, Alexandre Demoule,  
Julien Mayaux, Guillaume Geri, Eric Mariotte, Nicolas Bréchet, Nicolas de  
Prost, Mathieu Vautier, et al.

### ► To cite this version:

Adrien Mirouse, Antoine Parrot, Vincent Audigier, Alexandre Demoule, Julien Mayaux, et al.. Severe diffuse alveolar hemorrhage related to autoimmune disease: a multicenter study. *Critical Care*, 2020, 24 (1), 10.1186/s13054-020-02936-0 . hal-02625921

**HAL Id: hal-02625921**

**<https://hal.sorbonne-universite.fr/hal-02625921v1>**

Submitted on 26 May 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.


L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

RESEARCH

Open Access

# Severe diffuse alveolar hemorrhage related to autoimmune disease: a multicenter study



Adrien Mirouse<sup>1,2,3,4</sup> , Antoine Parrot<sup>5</sup>, Vincent Audigier<sup>6</sup>, Alexandre Demoule<sup>7</sup>, Julien Mayaux<sup>7</sup>, Guillaume Géri<sup>8</sup>, Eric Mariotte<sup>9</sup>, Nicolas Bréchet<sup>10</sup>, Nicolas de Prost<sup>11</sup>, Mathieu Vautier<sup>12</sup>, Mathilde Neuville<sup>13</sup>, Naïke Bigé<sup>14</sup>, Etienne de Montmollin<sup>15</sup>, Patrice Cacoub<sup>1,2,3,4</sup>, Matthieu Resche-Rigon<sup>6</sup>, Jacques Cadranet<sup>5</sup> and David Saadoun<sup>1,2,3,4\*</sup>

## Abstract

**Background:** Diffuse alveolar hemorrhage (DAH) occurs during the course of autoimmune disease and may be life threatening. The objective was to assess characteristics and prognosis factors of DAH who required intensive care unit (ICU) admission in patients with autoimmune diseases.

**Methods:** French multicenter retrospective study including patients presenting DAH related to autoimmune diseases requiring ICU admission from 2000 to 2016.

**Results:** One hundred four patients (54% of men) with median age of 56 [32–68] years were included with 79 (76%) systemic vasculitis and 25 (24%) connective tissue disorders. All patients received steroids, and 72 (69%), 12 (11.5%), and 57 (55%) patients had cyclophosphamide, rituximab, and plasma exchanges, respectively. During ICU stay, 52 (50%), 36 (35%), and 55 (53%) patients required mechanical ventilation, vasopressor use, and renal replacement therapy, respectively. Factors associated with mechanical ventilation weaning were age (HR [95%CI] 0.97 [0.96–0.99] per 10 years,  $p < 0.0001$ ), vasculitis-related DAH (0.52 [0.27–0.98],  $p = 0.04$ ), and time from dyspnea onset to ICU admission (0.99 [0.99–1] per day,  $p = 0.03$ ). ICU mortality was 15%. Factors associated with alive status at ICU discharge were chronic cardiac failure (HR [95%CI] 0.37 [0.15–0.94],  $p = 0.04$ ), antiphospholipid syndrome-related DAH (3.17 [1.89–5.32],  $p < 0.0001$ ), SAPS II (0.98 [0.97–0.99],  $p = 0.007$ ), and oxygen flow at ICU admission (0.95 [0.91–0.99] per liter/min,  $p = 0.04$ ).

**Conclusion:** DAH in autoimmune diseases is a life-threatening complication which requires mechanical ventilation in half of the cases admitted to ICU.

**Keywords:** Diffuse alveolar hemorrhage, ICU, mechanical ventilation, Plasma exchange, ANCA-associated vasculitis, Anti-MBG-associated vasculitis, IgA-associated vasculitis, Cryoglobulinemia, Systemic lupus erythematosus, Antiphospholipid syndrome

\* Correspondence: [david.saadoun@aphp.fr](mailto:david.saadoun@aphp.fr)

<sup>1</sup>Département Hospitalo-Universitaire  
Inflammation-Immunopathologie-Biothérapie (DHU i2B), UPMC Université  
Paris 06, UMR 7211, Sorbonne Universités, 75005 Paris, France  
<sup>2</sup>INSERM, UMR\_S 959, 75013 Paris, France

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Background

Diffuse alveolar hemorrhage (DAH) is a form of pulmonary hemorrhage that originates from the pulmonary microcirculation [1]. DAH is usually classified as immune or non-immune [2]. Immune causes represent 30 to 40% of all DAH cases [3]. Autoimmune diseases associated with DAH include mainly small-vessel vasculitis, systemic lupus erythematosus (SLE), and antiphospholipid syndrome (APS). Immune DAH severity is variable. It can range from asymptomatic forms, diagnosed on systematic chest radiography, to life-threatening complications. Severe forms may lead to acute respiratory failure and require intensive care unit (ICU) management [4]. DAH represents 12% of ICU admissions in patients with an autoimmune disease [5].

Early recognition and diagnosis are mandatory to initiate adequate treatments. Treatment is based on high-dose steroids in combination with cyclophosphamide or rituximab [6–8]. However, in this indication, these treatment regimens are based on case reports and small cohorts with immune DAH of heterogeneous severity. Plasma exchange therapy (PLEX) has been reported as efficient in several case series [9, 10]. PLEX has been reported as efficient in ANCA-associated vasculitis concerning 1-year renal outcome [11, 12]. These results were not confirmed in a recent phase III study in which plasma exchanges were not associated with end-stage renal disease rate reduction in ANCA-associated vasculitis [13].

Data regarding prognosis and outcome of severe DAH in autoimmune diseases are lacking as these patients are often excluded from large clinical trials [14–16]. In this French multicenter study, we aimed to assess the outcome and prognosis factors of severe DAH in autoimmune diseases and to compare vasculitis- and connective tissue disorder-related DAH.

## Methods

### Design

We conducted a retrospective French multicenter study in 11 ICU. This study was approved by the local ethics committee. All adult patients ( $\geq 18$  years old) with a severe DAH related to an autoimmune disease admitted in the participating ICUs between January 1, 2000, and January 1, 2017, were included. Patients were identified with the International Disease Classification 10 code for auto-immune diseases (lupus, vasculitis, inflammatory myopathy, systemic sclerosis, overlap autoimmune diseases, rheumatoid arthritis) and DAH. DAH was defined as (1) hemoptysis and/or macroscopically hemorrhagic broncho-alveolar lavage, (2) new pulmonary infiltrates, and (3) anemia. DAH was defined as severe if DAH management required ICU admission. Autoimmune diseases included were small-vessel vasculitis and

connective tissue disorders. Autoimmune diseases were diagnosed according to international diagnosis criteria [17–19]. Patients were excluded if DAH at admission was related to a non-immune condition such as heart failure or infection. Patients were identified from the ICU databases using codes for acute respiratory failure and for autoimmune diseases. All patients' medical records were reviewed by 2 investigators (AM and DS).

### Data collection

Demographic data, comorbidities, treatments, medical history, and clinical, biological, and radiological findings were abstracted from medical charts. Comorbidities were assessed with the Charlson comorbidity index [20]. Autoimmune diseases manifestations at ICU admission were collected including skin, neurological, joint, gut, and kidney manifestations. Physiological variables, laboratory data, and radiographic findings (chest X-ray and computed tomography [CT] when available) at ICU admission were also reported. Disease severity was assessed using the Simplified Acute Physiology Score (SAPS II) [21]. Patients were classified as having acute respiratory failure if they met the following criteria: severe dyspnea at rest, respiratory rate greater than 30 breaths per minute or clinical signs of respiratory distress, and oxygen saturation less than 92% or PaO<sub>2</sub> less than 60 mmHg on room air [22]. Hypoxemia severity was assessed using the PaO<sub>2</sub>/FiO<sub>2</sub> ratio. Fiberoptic bronchoscopy, bronchoalveolar lavage, and the use of life-sustaining treatments (i.e., noninvasive or invasive mechanical ventilation, renal replacement therapy, and vasopressors) were recorded. Diagnosis of the autoimmune disease was made according to the clinical, biological, immunological, and histological findings. Acute respiratory distress syndrome (ARDS) was defined according to the Berlin definition [23]. Acute kidney injury was defined according to the Kidney Disease Improving Global Outcomes definitions [24]. Therapeutic regimens were reported including red blood cell transfusions, standard dose steroids, high-dose steroid pulses, other immunosuppressive therapies, and plasma exchange therapy. ICU-acquired infections were recorded. The diagnosis of infection was confirmed if patients met both following criteria: microbiological identification of a pathogen and administration of related antibiotic treatment.

Mechanical ventilation weaning was defined as extubation without reintubation during the following 48 h. ICU and hospital length of stays and vital status at ICU and hospital discharge were obtained for all patients.

### Statistics

Patients' characteristics were described using medians and interquartile ranges for quantitative variables and counts and percentages for qualitative variables.

Characteristics of patients requiring mechanical ventilation during their ICU stay were compared to those of patients without mechanical ventilation using either the Wilcoxon rank sum test or Fishers' exact test. Comparisons between patients having received plasma exchanges and not, between those being deceased and being discharged alive, and between those having developed a vasculitis and a connective tissue disorder were performed in the same way. To assess variables associated with the weaning of mechanical ventilation, clinical relevant baseline characteristics significantly associated with the weaning from mechanical ventilation, as well as treatments provided during ICU stay, were included in a multivariate Cox model, where treatment variables are time-varying covariates and death in ICU is considered as a competing event of discharge alive from ICU. The same procedure was used for assessing variables associated with ICU discharge.

## Results

### Clinical characteristics of DAH

During the study period, we identified 104 patients (54% of men) admitted to the ICU for severe DAH associated with autoimmune disease (Table 1 and supplementary e-Table 1). The median age was 56 [32–68] years old. DAH was associated with an autoimmune disease relapse in 28 (27%) patients. DAH was the first autoimmune disease manifestation in 35 (34%) patients. A pneumo-renal syndrome was present in 83 (81%) patients. The median time from onset of respiratory symptoms to ICU admission was 5 [1–21] days. On admission, patients were severely hypoxemic with a PaO<sub>2</sub>/FiO<sub>2</sub> ratio of 150 [87–229] mmHg. Hemoptysis was present in 53 (51%) patients, and acute respiratory failure was reported in 78 (75%) patients. Lactate dehydrogenase (LDH) elevation was present in 65 (63%) patients. Bronchoscopy was performed in 83 (80%) patients and demonstrated macroscopic pulmonary hemorrhage in all cases.

### Comparison between patients with connective tissue disorder and vasculitis

A diagnosis of autoimmune disease was made 5 [2–11] days after hospital admission and 0 [–1 to 2] days after ICU admission. A small-vessel vasculitis was diagnosed in 79 (76%) patients, and a connective tissue disorder in 25 (24%). Organ involvement of the autoimmune disease was histologically confirmed in 49 (47%) cases. Comparison between patients with connective tissue disorder and vasculitis is shown in Table 1. Patients with vasculitis were older (61 [39–71] vs. 42 [27–55] years old,  $p = 0.003$ ) and were more often males (61% vs. 29%,  $p = 0.01$ ). Pneumo-renal syndrome was more frequent in patients with a vasculitis diagnosis (89% vs. 56%,  $p =$

0.0009). Dyspnea evolution was more acute in patients with a connective tissue disorder (time from dyspnea onset to ICU admission 1 [0–10] day vs. 6 [1–24] days,  $p = 0.018$ ). Patients with a connective tissue disorder had lower platelet counts and higher LDH levels on ICU admission.

All patients but one received a specific treatment based on steroids, and 93 (89%) patients received adjunctive steroid pulse therapy. An immunosuppressive therapy based on cyclophosphamide or rituximab was initiated in 72 (69%) and 12 (11.5%) patients, respectively. Cyclophosphamide and rituximab were associated in 6 (6%) patients. PLEX was initiated in 57 (55%) patients. Patients who received PLEX tended to be more severe at ICU admission (SAPS II: 37.5 [28–49.5] vs. 32.5 [22–41.75],  $p = 0.073$ ). In univariate analysis, there was no difference in mortality between patients treated or not with PLEX (supplementary eTable-2).

### Invasive mechanical ventilation requirement, weaning, and ICU management

Noninvasive mechanical ventilation was implemented in 33 (32%) patients, failing in 18 (55%) who were subsequently intubated. Invasive mechanical ventilation was required in 52 (50%) patients overall, of whom all fulfilled the ARDS criteria. Patients were intubated 0 [0–2] days after ICU admission. Univariate analysis of factors associated with mechanical ventilation requirement is displayed in Table 2. Duration of mechanical ventilation was 12 [6–22] days. Univariate analysis of factors associated with mechanical ventilation weaning is shown in supplementary e-Table 3. In multivariate analysis, factors associated with a longer mechanical ventilation weaning were age (HR [95%CI] 0.97 [0.96–0.99] per 10 years,  $p < 0.0001$ ), vasculitis (0.52 [0.27–0.98], 0.04), and time from dyspnea onset to ICU admission (0.99 [0.99–1] per day,  $p = 0.03$ ) (Fig. 1). The median ICU length of stay was 11 [7–18.8] days.

### Factors associated with ICU survival

Sixteen (15%) patients died in ICU. Death was attributed directly to refractory autoimmune disease in 5 (31%) cases, to refractory ARDS in 4 (25%) cases, to multi-organ failure in 4 (25%) cases, and to septic shock in 3 (19%) cases. In univariate analysis, factors associated with ICU mortality are displayed in Table 3 and supplementary e-Table 4. In multivariate analysis, factors associated with alive status at ICU discharge were chronic heart failure (HR [95%CI] 0.37 [0.15–0.94],  $p = 0.037$ ), APS-related DAH (3.17 [1.89–5.32],  $p < 0.0001$ ), SAPS II (0.98 [0.97–0.99],  $p = 0.007$ ), and oxygen flow at ICU admission (0.95 [0.91–0.998],  $p = 0.04$ ) (Fig. 2).

After ICU discharge, 48 (55%) patients were followed up with a median duration of 19 [8–38] months. At the

**Table 1** Characteristics of 104 patients with DAH and according to the presence of a vasculitis or a connective tissue disorder

|   | All patients (n = 104) | Connective tissue disorder (n = 25) | Vasculitis (n = 79) | p        |
|---|------------------------|-------------------------------------|---------------------|----------|
| <b>A. Baseline characteristics</b>                        |                        |                                     |                     |          |
| <b>Demographics</b>                                       |                        |                                     |                     |          |
| Age, years, median [IQR]                                  | 56 [32–68]             | 42 [27–55]                          | 61 [39–71]          | 0.003    |
| Male gender, n (%)  | 56 (54%)               | 7 (29%)                             | 48 (61%)            | 0.02     |
| <b>Comorbidities</b>                                      |                        |                                     |                     |          |
| Charlson score, median [IQR]                              | 3 [1–4]                | 2 [1–3.5]                           | 3 [1–4]             | 0.23     |
| Previous steroid treatment, n (%)                         | 26 (25%)               | 10 (40%)                            | 16 (20%)            | 0.064    |
| <b>Systemic disease, n (%)</b>                            |                        |                                     |                     |          |
| Connective tissue disorder                                | 25 (24%)               | NA                                  | NA                  |          |
| Systemic lupus erythematosus                              | 12 (48%)               |                                     |                     |          |
| Primary antiphospholipid syndrome                         | 9 (36%)                |                                     |                     |          |
| Others*   | 4 (16%)                |                                     |                     |          |
| Vasculitis  | 79 (76%)               | NA                                  | NA                  |          |
| ANCA-associated vasculitis                                | 57 (72%)               |                                     |                     |          |
| Anti-GBM disease  | 12 (15%)               |                                     |                     |          |
| Cryoglobulin-associated vasculitis                        | 4 (5%)                 |                                     |                     |          |
| IgA-associated vasculitis                                 | 6 (8%)                 |                                     |                     |          |
| Inaugural   | 76 (73%)               | 13 (52%)                            | 63 (80%)            | 0.01     |
| Relapse   | 28 (27%)               | 12 (48%)                            | 16 (20%)            |          |
| <b>Systemic disease manifestations, n (%)</b>             |                        |                                     |                     |          |
| DAH   | 104 (100%)             | 25 (100%)                           | 79 (100%)           | 1        |
| Hemoptysis  | 53 (51%)               | 10 (40%)                            | 43 (54%)            | 0.25     |
| Cough   | 68 (65%)               | 17 (68%)                            | 51 (65%)            | 0.81     |
| Acute respiratory failure                                 | 78 (75%)               | 20 (80%)                            | 58 (73%)            | 0.6      |
| Renal   | 83 (81%)               | 14 (56%)                            | 69 (89%)            | 0.0009   |
| Digestive   | 7 (7%)                 | 2 (8%)                              | 5 (6%)              | 0.68     |
| Nervous system  | 16 (16%)               | 6 (24%)                             | 10 (13%)            | 0.21     |
| Joint   | 20 (19%)               | 4 (16%)                             | 16 (21%)            | 0.78     |
| Skin  | 23 (22%)               | 7 (28%)                             | 16 (21%)            | 0.42     |
| <b>ICU admission characteristics, median [IQR]</b>        |                        |                                     |                     |          |
| SAPS II   | 36 [25.75–47]          | 33 [26–42]                          | 38 [26–48]          | 0.51     |
| Temperature   | 37.9 [37–38.6]         | 38.2 [37.2–39.1]                    | 37.7 [37–38.5]      | 0.15     |
| Oxygen flow, L/min  | 15 [5–15]              | 12 [5–15]                           | 15 [5–15]           | 0.92     |
| PaO <sub>2</sub> /FiO <sub>2</sub> ratio                  | 150 [87–229]           | 120 [90–230]                        | 157 [86–225]        | 0.64     |
| Time (days) from dyspnea onset to ICU admission           | 5 [1–21]               | 1 [0–10]                            | 6 [1–24]            | 0.018    |
| Time (days) from first symptoms to ICU admission          | 30 [11.8–79]           | 17 [10–46]                          | 32 [15–88]          | 0.079    |
| Time (days) from hospital admission to ICU admission      | 5 [1–12]               | 7 [3–15]                            | 3 [0–12]            | 0.13     |
| <b>Biological findings at ICU admission, median [IQR]</b> |                        |                                     |                     |          |
| Hemoglobin, g/L   | 86 [72–95]             | 87 [75–97]                          | 86 [72–95]          | 0.73     |
| Leukocytes, G/L   | 11.7 [8.9–15.6]        | 11.1 [6.4–17.1]                     | 11.7 [9.2–15.4]     | 0.47     |
| Platelets count, G/L                                      | 257 [141–353]          | 102 [53–236]                        | 278 [186–401]       | < 0.0001 |
| Creatinine, μmol/L  | 235 [92–433]           | 103 [71–174]                        | 303 [128–520]       | 0.0002   |
| Urine protein/creatinine, g/mmol                          | 0.19 [0.1–0.33]        | 0.12 [0.07–0.25]                    | 0.2 [0.1–0.34]      | 0.17     |
| LDH, mmol/L   | 488 [354–905]          | 873 [532–1152]                      | 454 [329–714]       | 0.008    |
| <b>B. ICU management.</b>                                 |                        |                                     |                     |          |

**Table 1** Characteristics of 104 patients with DAH and according to the presence of a vasculitis or a connective tissue disorder (Continued)

|   | All patients (n = 104) | Connective tissue disorder (n = 25) | Vasculitis (n = 79) | p        |
|---|------------------------|-------------------------------------|---------------------|----------|
| <b>ICU management, n (%)</b>                        |                        |                                     |                     |          |
| Vasopressor use                                     | 36 (35%)               | 8 (32%)                             | 28 (35%)            | 0.81     |
| Renal replacement therapy                           | 55 (53%)               | 6 (24%)                             | 49 (62%)            | 0.001    |
| Respiratory management                              |                        |                                     |                     |          |
| Non-invasive ventilation                            | 33 (32%)               | 8 (32%)                             | 25 (32%)            | 1        |
| Mechanical ventilation                              | 52 (50%)               | 11 (44%)                            | 41 (52%)            | 0.65     |
| ARDS diagnosis                                      | 52 (50%)               | 13 (52%)                            | 43 (55%)            | 0.82     |
| Prone positioning                                   | 11 (21%)               | 3 (12%)                             | 8 (11%)             | 1        |
| Mechanical ventilation duration, days, median [IQR] | 12 [6–22]              | 4 [4–18]                            | 13 [9–33]           | 0.007    |
| Red blood cell transfusion                          | 78 (75%)               | 16 (64%)                            | 62 (80%)            | 0.33     |
| <b>Systemic disease management, n (%)</b>           |                        |                                     |                     |          |
| Time (days) from first symptoms to diagnosis        | 31 [11.5–77]           | 19.5 [10–53]                        | 32 [15–86]          | 0.14     |
| Steroids  | 103 (99%)              | 25 (100%)                           | 78 (99%)            | 1        |
| Steroids pulse therapy                              | 93 (89%)               | 20 (80%)                            | 73 (92%)            | 0.13     |
| Cyclophosphamide                                    | 72 (69%)               | 9 (36%)                             | 63 (80%)            | < 0.0001 |
| Rituximab   | 12 (11.5%)             | 1 (4%)                              | 11 (14%)            | 0.29     |
| PLEX  | 57 (55%)               | 6 (24%)                             | 51 (65%)            | 0.0009   |
| Number of PLEX                                      | 7 [4.3–9.5]            | 4 [2–9]                             | 7 [5–9]             | 0.32     |
| <b>Bacterial superinfection, n (%)</b>              | 30 (29%)               | 3 (12%)                             | 27 (34%)            | 0.042    |
| <b>Hospital mortality, n (%)</b>                    | 16 (15%)               | 3 (12%)                             | 13 (17%)            | 0.76     |
| <b>Follow-up</b>                                    | 48 (55%)               | 13 (59%)                            | 35 (53%)            | 0.65     |
| Length of follow-up (months)                        | 19 [8–38]              | 37 [11–66]                          | 15 [7–28]           | 0.003    |
| Chronic renal failure**                             | 22 (65%)               | 4 (80%)                             | 18 (62%)            | 0.33     |
| Dialysis**  | 8 (24%)                | 1 (20%)                             | 7 (24%)             | 0.42     |

\*Other connective tissue disorders: mixed connective tissue disorder (3 patients) and myositis (1 patient)


\*\*Percentage based on the number of followed up patients at risk (patients with pneumo-renal syndrome at admission and with follow-up available)

Abbreviations: ANCA anti-neutrophil cytoplasmic antibody, ARDS acute respiratory distress syndrome, DAH diffuse alveolar hemorrhage, GC glucocorticoid, ICU intensive care unit, LDH lactate dehydrogenase, NA not applicable, PLEX plasma exchange, SAPS Simplified Acute Physiology Score

**Table 2** Univariate analysis of factors associated with mechanical ventilation requirement

| Parameters  | No invasive ventilation<br>n = 52 | Invasive ventilation<br>n = 52 | p value  |
|---|-----------------------------------|--------------------------------|----------|
| Age, years, median [IQR]                                      | 50 [29–62]                        | 58 [39–70]                     | 0.12     |
| Charlson comorbidity index, median [IQR]                      | 3 [1.3–4.8]                       | 3 [1–4]                        | 0.59     |
| Vasculitis, yes, n (%)  | 38 (73%)                          | 41 (79%)                       | 0.65     |
| Hemoptysis, yes, n (%)  | 30 (58%)                          | 23 (44%)                       | 0.24     |
| Acute respiratory failure, n (%)                              | 28 (54%)                          | 50 (96%)                       | < 0.0001 |
| Renal involvement, yes, n (%)                                 | 40 (77%)                          | 43 (84%)                       | 0.46     |
| SAPS II, median [IQR]   | 29 [19–37]                        | 44 [33–56]                     | < 0.0001 |
| PaO <sub>2</sub> /FiO <sub>2</sub> ratio, median [IQR]        | 205 [123–263]                     | 108 [75–190]                   | 0.0003   |
| Time (days) from dyspnea to ICU admission, days, median [IQR] | 6 [1–23]                          | 5 [1–16]                       | 0.70     |
| Hemoglobin at day 1, median [IQR]                             | 8.3 [7.4–9.5]                     | 8.6 [7.2–9.5]                  | 0.85     |
| Neutrophil count at day 1, median [IQR]                       | 8.2 [6.4–10.2]                    | 10.6 [7.6–18.0]                | 0.05     |
| LDH at day 1, U/L, median [IQR]                               | 432 [317–626]                     | 679 [409–1213]                 | 0.010    |

Abbreviations: CI confidence interval, HR hazard ratio, ICU intensive care unit, SHR subdistribution hazard ratio



end of follow-up, 22 (65%) of these patients had a chronic kidney disease and 8 (24%) still required renal replacement therapy. Twenty-two (47%) patients had a lung CT-scan evaluation during follow-up showing lung fibrosis for 8 (36%) patients. Pulmonary function testing was performed in 15 (32%) patients and showed a restrictive pulmonary disorder in 6 (40%) cases.

**Discussion**

In this multicenter nationwide French study, we report the largest study assessing the outcome and prognosis factors associated with severe DAH related to autoimmune diseases. The conclusions drawn by this study are that (1) ICU mortality was 16% reaching 31% in patients requiring mechanical ventilation; (2) mechanical ventilation was required in half of the cases, of whom all met ARDS criteria; and (3) systemic vasculitis was associated with longer mechanical ventilation duration.

Other studies have reported management and outcomes of patients with DAH, but they have described patients with less severe diseases. Cartin-Ceba et al. have reported outcomes of patients with AAV-related DAH [10]. Some of these patients were asymptomatic and were not hospitalized. Other patients in this study required ICU admission, but they were less severe than in our cohort. Another cohort included patients with variable severity, and DAH was not confirmed by bronchoalveolar lavage in all cases [25].

In the present study, overall ICU mortality was 16% and reached 31% of patients who required mechanical

ventilation. Mortality from DAH has reduced during the past years, and the mortality in our cohort is in line with recent DAH cohorts [26, 27]. Major advances in the care of critically ill patients could explain these results. Our results point out that severity at ICU admission is directly linked to ICU mortality. Chronic heart failure has already been reported as associated with a poorer prognosis in patients with DAH [3]. DAH related to autoimmune disease is considered to have a better prognosis compared to non-immune causes of DAH [3, 28]. This may illustrate the benefit of early aggressive immunosuppressive therapies in this context. However, there is no data comparing prognosis of DAH according to autoimmune diseases. In our study, APS diagnosis was associated with a better outcome. Previous studies of APS-related DAH reported good outcomes when DAH was controlled [9, 29]. Although our study was not designed to address this question, neither immunosuppressants nor PLEX therapy seemed to improve prognosis.

Half of the patients required invasive mechanical ventilation. Comorbidities and type of autoimmune disease were not risk factors for mechanical ventilation. These results are in agreement with previous studies, suggesting that the underlying medical context is no longer significantly associated with the risk for intubation after adjustment on the severity of the acute disease [30–33]. Age and small-vessel vasculitis were associated with a longer duration of mechanical ventilation. Patients with small-vessel vasculitis required more frequently renal replacement therapy which could explain in part a

**Table 3** Univariate analysis of ICU survival associated factors

| Parameter  | Univariate analysis |                |
|--|---------------------|----------------|
|  | SHR 95%CI           | <i>p</i> value |
| Age (per 10 years)   | 0.87 (0.79–0.95)    | 0.0016         |
| Sex  | 1.12 (0.75–1.7)     | 0.58           |
| Charlson comorbidity index                                   | 0.88 (0.81–0.97)    | 0.0078         |
| Chronic respiratory failure                                  | 0.73 (0.29–1.82)    | 0.49           |
| Chronic cardiac failure                                      | 0.34 (0.16–0.74)    | 0.0063         |
| Chronic renal failure  | 0.59 (0.3–1.17)     | 0.13           |
| Steroid treatment  | 0.78 (0.44–1.37)    | 0.38           |
| Connective tissue disorder                                   | 1.35 (0.82–2.22)    | 0.24           |
| Systemic lupus   | 1.07 (0.48–2.41)    | 0.86           |
| Antiphospholipid syndrome                                    | 2.26 (1.35–3.78)    | 0.0018         |
| Other systemic disease                                       | 0.87 (0.36–2.09)    | 0.76           |
| Vasculitis   | 1.35 (0.82–2.22)    | 0.24           |
| ANCA-associated vasculitis                                   | 0.95 (0.62–1.45)    | 0.8            |
| Goodpasture syndrome   | 1.08 (0.7–1.66)     | 0.73           |
| Cryoglobulin-associated vasculitis                           | 0.17 (0.02–1.68)    | 0.13           |
| IgA-associated vasculitis                                    | 0.49 (0.15–1.6)     | 0.24           |
| Relapse  | 1.07 (0.63–1.81)    | 0.81           |
| Hemoptysis   | 1.18 (0.79–1.77)    | 0.42           |
| Acute respiratory failure                                    | 0.57 (0.37–0.89)    | 0.014          |
| Renal involvement  | 0.73 (0.46–1.14)    | 0.17           |
| Digestive involvement  | 1.31 (0.45–3.85)    | 0.62           |
| Nervous system involvement                                   | 1.21 (0.78–1.87)    | 0.39           |
| Joint involvement  | 0.8 (0.48–1.34)     | 0.41           |
| Skin involvement   | 0.81 (0.48–1.36)    | 0.43           |
| Other systemic disease manifestations                        | 1.1 (0.93–1.3)      | 0.25           |
| SAPS II  | 0.97 (0.96–0.99)    | < 0.0001       |
| Oxygen flow  | 0.95 (0.91–0.98)    | 0.0032         |
| PAO <sub>2</sub> over FiO <sub>2</sub> ratio (per 10 points) | 1.02 (1–1.04)       | 0.0099         |
| Time (days) from dyspnea onset to ICU admission              | (0.98–1)            | 0.13           |
| Time (days) from hospital admission to ICU admission         | 1.01 (0.98–1.04)    | 0.6            |
| Hemoglobin at ICU admission                                  | 0.97 (0.89–1.05)    | 0.41           |
| Lymphocytes at ICU admission                                 | 2.51 (1.6–3.95)     | < 0.0001       |
| Neutrophil count at ICU admission                            | 1.02 (0.98–1.06)    | 0.45           |
| Platelets count at ICU admission (per 10G/L)                 | 1.01 (0.99–1.02)    | 0.36           |
| Creatinine at ICU admission (per 10 μmol/L)                  | 1 (0.99–1.01)       | 0.72           |
| Urine protein/creatinine ratio                               | 0.97 (0.46–2.02)    | 0.93           |
| LDH at ICU admission (per 100UI/L)                           | 0.98 (0.94–1.02)    | 0.31           |
| Vasopressor use  | 0.29 (0.18–0.47)    | < 0.0001       |


*Abbreviations:* CI confidence interval, HR hazard ratio, ICU intensive care unit, SAPS Simplified Acute Physiology Score, SHR cause specific hazard ratio

negative impact on ventilation weaning [34]. Early ICU admission after dyspnea onset was associated with a shorter duration under mechanical ventilation. Dumas et al. already reported that direct ICU admission was

associated with better outcomes in a large study of critically ill patients with systemic rheumatic disease [5].

Our study has several limitations. First, given the retrospective design over a long period of time,





supportive care practices may have changed throughout the study period and influenced the results. Second, for the diagnosis of DAH, we used a database encoded by physicians at patient ICU discharge and we cannot exclude that some patients with autoimmune disease-related DAH had been missed. Third, we mixed patients with different autoimmune diseases which mean different prognosis and different management. However, most patients were admitted before autoimmune disease diagnosis. This study might provide some practical data to initially manage these patients with a DAH and a suspected autoimmune disease.

**Conclusion**

In conclusion, DAH related to autoimmune disease is a rare but potentially dreadful complication that requires mechanical ventilation in half of the cases admitted to ICU. Age, small-vessel vasculitis, and the time from dyspnea onset to ICU admission were associated with a longer mechanical ventilation duration. The best initial regimen remains to be determined.

**Supplementary information**

Supplementary information accompanies this paper at <https://doi.org/10.1186/s13054-020-02936-0>.

**Additional file 1: Table S1.** supplementary data on patients with DAH and according to the presence of a vasculitis or a connective tissue disorder. **Table S2.** univariate analysis according to plasma exchange

therapy. **Table S3.** Univariate analysis of factors associated with mechanical ventilation weaning. **Table S4.** Univariate analysis of respiratory and vital status outcomes according to diffuse alveolar hemorrhage treatment.

**Abbreviations**

ARDS: Acute respiratory distress syndrome; ANCA: Anti-neutrophil cytoplasmic antibodies; APS: Antiphospholipid syndrome; DAH: Diffuse alveolar hemorrhage; ICU: Intensive care unit; LDH: Lactate dehydrogenase; PLEX: Plasma exchange therapy; SAPS II: Simplified Acute Physiology Score; SLE: Systemic lupus erythematosus

**Acknowledgements**

None.

**Authors' contributions**

AM, MRR, and DS have made substantial contributions to the conception, the design of the work, and the acquisition, analysis, and interpretation of data and have drafted the work or substantively revised it. They have approved the submitted version (and any substantially modified version that involves the author's contribution to the study). They have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even the ones in which the author was not personally involved, are appropriately investigated and resolved, and the resolution documented in the literature. AP, VA, AD, JM, GG, EM, NB, NdP, MV, MN, NB, EdM, PC, and JC have made substantial contributions to the acquisition and analysis of data. They have approved the submitted version (and any substantially modified version that involves the author's contribution to the study). They have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even the ones in which the author was not personally involved, are appropriately investigated and resolved, and the resolution documented in the literature.

**Funding**

None.

**Availability of data and materials**

Not available.

**Ethics approval and consent to participate**

According to the French law, a waiver of consent was obtained. The study was approved by local Ethic Committee.

**Consent for publication**

Not applicable.

**Competing interests**

None.

**Author details**

<sup>1</sup>Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biothérapie (DHU i2B), UPMC Université Paris 06, UMR 7211, Sorbonne Universités, 75005 Paris, France. <sup>2</sup>INSERM, UMR\_S 959, 75013 Paris, France. <sup>3</sup>CNRS, FRE3632, 75005 Paris, France. <sup>4</sup>Département de Médecine Interne et Immunologie Clinique, National Center for Autoimmune and Systemic Diseases and National Center for Autoinflammatory Diseases and Amyloidosis, APHP, Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France. <sup>5</sup>Service de Pneumologie, Hôpital Tenon, APHP, Paris, France. <sup>6</sup>Département de Biostatistiques, Hôpital Saint-Louis, APHP, Paris, France. <sup>7</sup>Service de Réanimation Médicale et Pneumologie, Hôpital Pitié-Salpêtrière, APHP, Paris, France. <sup>8</sup>Service de Réanimation Médicale, Hôpital Saint-Louis, APHP, Paris, France. <sup>9</sup>Service de Réanimation Médicale, Hôpital Henri Mondor, APHP, Créteil, France. <sup>10</sup>Service de Réanimation Médicale, Hôpital Pitié-Salpêtrière, APHP, Paris, France. <sup>11</sup>Service de Réanimation Médicale, Hôpital Henri Mondor, APHP, Créteil, France. <sup>12</sup>Service de Médecine Interne, CHU de Caen, Caen, France. <sup>13</sup>Service de Réanimation Médicale, Hôpital Bichat, APHP, Paris, France. <sup>14</sup>Service de Réanimation Médicale, Hôpital Saint-Antoine, Paris, France. <sup>15</sup>Service de Réanimation Médico-chirurgicale, Hôpital Delafontaine, Saint-Denis, France.

Received: 19 November 2019 Accepted: 30 April 2020

Published online: 18 May 2020

**References**

- Collard HR, Schwarz MI. Diffuse alveolar hemorrhage. *Clin Chest Med*. 2004; 25:583–92 vii.
- Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. *Chest*. 2010;137:1164–71.
- de Prost N, Parrot A, Cuquemelle E, Picard C, Antoine M, Fleury-Feith J, et al. Diffuse alveolar hemorrhage in immunocompetent patients: etiologies and prognosis revisited. *Respir Med*. 2012;106:1021–32.
- Demisselle J, Auchabie J, Beloncle F, Gatault P, Grangé S, Du Cheyron D, et al. Patients with ANCA-associated vasculitis admitted to the intensive care unit with acute vasculitis manifestations: a retrospective and comparative multicentric study. *Ann Intensive Care*. 2017;7:39.
- Dumas G, Géri G, Montlahuc C, Chemam S, Dangers L, Pichereau C, et al. Outcomes in critically ill patients with systemic rheumatic disease: a multicenter study. *Chest*. 2015;148:927–35.
- Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Ann Rheum Dis*. 2016;75:1583–94.
- Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JHM, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. *Ann Rheum Dis*. 2012;71:1771–82.
- Tse JR, Schwab KE, McMahon M, Simon W. Rituximab: an emerging treatment for recurrent diffuse alveolar hemorrhage in systemic lupus erythematosus. *Lupus*. 2015;24:756–9.
- Cartin-Ceba R, Peikert T, Ashrani A, Keogh K, Wylam ME, Ytterberg S, et al. Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage. *Arthritis Care Res (Hoboken)*. 2014;66:301–10.
- Cartin-Ceba R, Diaz-Caballero L, Al-Qadi MO, Tryfon S, Fervenza FC, Ytterberg SR, et al. Diffuse alveolar hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: predictors of respiratory failure and clinical outcomes. *Arthritis Rheumatol (Hoboken, NJ)*. 2016;68:1467–76.
- Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol*. 2007;18:2180–8.
- Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine a for maintenance of remission in Wegener's granulomatosis—a clinical randomized controlled trial. *Nephrol Dial Transplant*. 2011;26:206–13.
- Walsh M, Merkel PA, Peh C-A, Szpirt WM, Puéchal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. *N Engl J Med*. 2020;382:622–31.
- de Groot K, Harper L, Jayne DRW, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med*. 2009;150:670–80.
- Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med*. 2010;363:211–20.
- Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med*. 2010;363:221–32.
- Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum*. 2012;64:2677–86.
- Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum*. 2013;65:1–11.
- Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost*. 2006;4: 295–306.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40:373–83.
- Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. *JAMA*. 1993;270:2957–63.
- Vincent J-L, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. *JAMA*. 2009;302:2323–9.
- ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA*. 2012;307:2526–2533.
- Acute Kidney Injury (AKI) – KDIGO [Internet]. [cited 2017 Sep 4]. Available from: <http://kdigo.org/guidelines/acute-kidney-injury/>.
- Kostianovsky A, Hauser T, Pagnoux C, Cohen P, Daugas E, Mouthon L, et al. Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients' features and prognostic factors. *Clin Exp Rheumatol*. 2012;30:577–82.
- Holguin F, Ramadan B, Gal AA, Roman J. Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. *Am J Med Sci*. 2008;336:321–6.
- Hruskova Z, Casian AL, Konopasek P, Svobodova B, Frausova D, Lanska V, et al. Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study. *Scand J Rheumatol*. 2013;42:211–4.
- Rabe C, Appenrodt B, Hoff C, Ewig S, Klehr HU, Sauerbruch T, et al. Severe respiratory failure due to diffuse alveolar hemorrhage: clinical characteristics and outcome of intensive care. *J Crit Care*. 2010;25:230–5.
- Yachoui R, Sehgal R, Amlani B, Goldberg JW. Antiphospholipid antibodies-associated diffuse alveolar hemorrhage. *Semin Arthritis Rheum*. 2015;44: 652–7.
- Lemiale V, Lambert J, Canet E, Mokart D, Pène F, Rabbat A, et al. Identifying cancer subjects with acute respiratory failure at high risk for intubation and mechanical ventilation. *Respir Care*. 2014;59:1517–23.
- Adda M, Coquet I, Darmon M, Thiery G, Schlemmer B, Azoulay E. Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure. *Crit Care Med*. 2008;36:2766–72.
- Antonelli M, Conti G, Moro ML, Esquinas A, Gonzalez-Diaz G, Confalonieri M, et al. Predictors of failure of noninvasive positive pressure ventilation in

patients with acute hypoxemic respiratory failure: a multi-center study. *Intensive Care Med.* 2001;27:1718–28.

33. Mirouse A, Vignon P, Piron P, Robert R, Papazian L, Géri G, et al. Severe varicella-zoster virus pneumonia: a multicenter cohort study. *Crit Care.* 2017; 21:137.
34. Kao K-C, Hu H-C, Fu J-Y, Hsieh M-J, Wu Y-K, Chen Y-C, et al. Renal replacement therapy in prolonged mechanical ventilation patients with renal failure in Taiwan. *J Crit Care.* 2011;26:600–7.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

